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Abstract
Introduction: The incidence rate of acromegaly is 50 to70 persons per one million people. It occurs twice as often in women than in men,
especially in middle age. In the course of the disease, insulin resistance develops, which is connected with the hypersecretion of soma-
totropin. Type 2 diabetes mellitus occurs more frequently in patients with acromegaly than in the rest of the population. It is diagnosed in
13–56% of acromegaly sufferers; impaired glucose tolerance occurs in 16–46% of examined patients with acromegaly.
The aim of this study is to estimate disturbances of glycaemia in patients with diagnosed acromegaly, hospitalized in the Endocrinology
and Diabetology Department of Collegium Medicum University of Nicolaus Copernicus in Bydgoszcz in the years 2001–2009.
Material and methods: The participants were a group of 70 patients with acromegaly diagnosed on the basis of clinical symptoms, high
levels of somatotropin, and MRI imaging of the pituitary gland.
Results: Type 2 diabetes was diagnosed in 19 patients (27%); there were 11 cases (15%) of diagnosis of impaired fasting glycaemia (IFG)
and imapired glucose tolerance (IGT) combined. Normoglycaemia was recognized in 57% of participants (40 patients). The average age of
participants with concomitant type 2 diabetes was 56.1 years, whereas the average age of those without carbohydrate metabolism distur-
bances was 47.1 years.
Conclusions: In patients with acromegaly, the incidence rate of type 2 diabetes is 3–4-times higher than in the rest of the population and
increases with age, especially after the age of 60. (Pol J Endocrinol 2010; 61 (3): 260–263)
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Streszczenie
Wstęp: Akromegalia występuje z częstością około 50–70 na milion osób, 2-krotnie częściej u kobiet niż u mężczyzn, szczególnie w średnim
wieku. W przebiegu akromegalii dochodzi do wystąpienia insulinooporności związanej z nadmiernym wydzielaniem hormonu wzrostu.
Cukrzyca typu 2 u pacjentów z akromegalią występuje częściej niż w populacji ogólnej. Stwierdza się ją u 13–56% pacjentów, natomiast
upośledzona tolerancja glukozy występuje u 16–46% badanych osób z akromegalią.
Celem pracy była ocena zaburzeń gospodarki węglowodanowej u pacjentów z rozpoznaną akromegalią, hospitalizowanych w Klinice
Endokrynologii i Diabetologii Collegium Medicum Uniwersytetu Mikołaja Kopernika w Bydgoszczy w latach 2001–2009.
Materiał i metody: W pracy przedstawiono 70 pacjentów z akromegalią rozpoznaną na podstawie podwyższonego stężenia hormonu
wzrostu, obrazu klinicznego oraz badania MRI przysadki.
Wyniki: Cukrzycę typu 2 u osób z rozpoznaną akromegalią stwierdzono u 19 pacjentów (27%), natomiast nieprawidłową glikemię na
czczo (IFG, impaired fasting glycaemia) i upośledzoną tolerancją glukozy (IGT, impaired glucose tolerance) łącznie u 11 z nich (15%). Pacjenci
z normoglikemią stanowili w badanej populacji 57% (40 pacjentów). W grupie przebadanych 70 osób z rozpoznaną akromegalią, średni
wiek osób z towarzyszącą cukrzycą typu 2 wynosił 56,1 lat w stosunku do osób bez zaburzeń gospodarki węglowodanowej — 47,1 lat.
Wnioski: U pacjentów z akromegalią częstość występowania cukrzycy typu 2 jest 3–4-krotnie większa niż w populacji ogólnej i rośnie
wraz z wiekiem, szczególnie po 60. roku życia. (Endokrynol Pol 2010; 61 (3): 260–263)
Słowa kluczowe: akromegalia, cukrzyca, IFG, IGT
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The incidence rate of acromegaly is 50 to70 persons per
one million people. It occurs twice as often in women
than in men, especially in middle age. In the course of
the disease, insulin resistance develops, which is con-
nected with the hypersecretion of somatotropin, which
disturbs insulin activity both in the liver and peripheral
tissues [1].
Somatotropin also increases lipolysis of adipose tis-
sue, boosting the amount of free fatty acids in blood
serum, and increasing insulin resistance, which results
in aberrations in carbohydrate metabolism [2–4].
Type 2 diabetes mellitus occurs more frequently in
patients with acromegaly than in the rest of the popu-
lation [2, 5]. It is diagnosed in 13–56% of acromegaly
sufferers; impaired glucose tolerance occurs in 16–46%
of examined patients with acromegaly [2–4, 6–8].
However, impaired fasting glucose occurs in approx-
imately 19% of patients with acromegaly [2].
The aim of this study was to examine the influence
of somatotropin on aberrations in glycaemia in patients
with (active/diagnosed) acromegaly, hospitalized in the
Endocrinology and Diabetology Department of Colle-
gium Medicum University of Nicolaus Copernicus in
Bydgoszcz in the years 2001–2009.
Material and methods
The study group consisted of 70 patients (44 women
and 26 men; aged 19 to 76 years) with acromegaly diag-
nosed on the basis of clinical symptoms, high level of
somatotropin, and MRI imaging of the pituitary gland.
All patients were hospitalized in the Endocrinology
and Diabetology Department of Collegium Medicum
University of Nicolaus Copernicus in Bydgoszcz in the
years 2001–2009.
Round-the-clock glucose profiles of the participants
was marked; oral glucose tolerance tests were also
conducted in cases of impaired fasting glucose (IFG)
(> 100 mg/dL) or postprandial glucose (140–200 mg/dL).
Results
Type 2 diabetes was diagnosed in 19 patients (27%). There
were 11 cases (15%) of diagnosis of IFG and impaired
glucose tolerance (IGT) combined. Normoglycaemia was
recognized in 57% of participants (40 patients) (Table I).
The average age of participants with concomitant
type 2 diabetes was 56.1 years, whereas the average age
of those without carbohydrate metabolism disturbanc-
es was 47.1 years. This difference was less in females
than in males (F — 55 v. 50.8; M — 57.3 v. 36). The average
age of patients with IFG and IGT was 49.6 years (Table II).
The participants were divided into four subgroups
according to their age (20–30; 31–50; 51–60; >60). The
group with the largest number of participants com-
prised the patients aged from 31 to 60, i.e. 54 patients
(77%).
Aberrations of carbohydrate metabolism in cases of
IFG, IGT, and type 2 diabetes mellitus occurred with
similar frequency in all age subgroups except for the
group of participants aged 60 and over, in which a sig-
nificant increase of the percentage of patients with type
2 diabetes mellitus was observed, in comparison to those
with normoglycaemia. Patients with IFG and IGT aged
60 years and over did not show changes compared with
those under 60 (Table III).
Table I. Aberrations in carbohydrate metabolism in patients
with acromegaly according as sex
Tabela I. Zaburzenia gospodarki węglowodanowej
u pacjentów z akromegalią w zależności od płci
Acromegaly Normoglycaemia IFG + IGT Type 2
diabetes
All n = 40 n = 11 n = 19
(n = 70) (57%)  (15.7%)  (27%)
Female n = 30 n = 4 n = 10
(n = 44)  (68%)  (9%)  (22.7%)
Male n = 10 n = 7 n = 9
(n = 26)  (38.5%)  (26.9%)  (34.7%)
Table II . Aberrations in carbohydrate metabolism in patients with acromegaly according as average age
Tabela II. Zaburzenia gospodarki węglowodanowej u pacjentów z akromegalią w zależności od średniego wieku
Average age of patients with acromegaly Normoglycaemia IFG + IGT Type 2 diabetes
(years) (years) (years)
All (n = 70) 47.1 49.6 56.1
Female (n = 44) 50.8 49.2 55
Male (n = 26) 36 49.8 57.3
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In patients with acromegaly and aberrations of car-
bohydrate metabolism such as type 2 diabetes mellitus,
the average level of fasting glucose was 128 mg/dL. In
these cases average postprandial glycaemia was 163 mg/
/dL, while average twenty-four-hour glycaemia was
158 mg/dL (Table IV).
Discussion
Acromegaly is an endocrinopathy which causes the
development of insulin resistance. Therefore, there is a
higher occurrence rate of aberrations in carbohydrate
metabolism in patients with acromegaly.
In patients with diagnosed acromegaly, type 2 dia-
betes mellitus occurs 3.7 times more often than in the
rest of the population (20 v. 5.37%) [9, 10]. Stelmachows-
ka-Banaś et al., who examined the Polish acromegaly
population, found type 2 diabetes in 20% of patients,
IGT in 15% of patients, and IFG in 19% of patients [9,
10].
In this study there were 70 patients with diagnosed
acromegaly. In 43% of them aberrations in carbohydrate
metabolism were observed. Type 2 diabetes was found
in 27% of patients. This was approximately 7% more
than in Stelmachowskaa-Banaś et al. study. Impaired
fasting glucose and impaired glucose tolerance occurred
in 15% of cases, whereas Stelmachowska observed it in
34% of cases.
Increased risk of aberrations in carbohydrate metab-
olism in patients with acromegaly was observed by
Resmini and his collaborators. They proved it was de-
pendent on somatotropin concentration, duration of the
disease, and the age of the patient. However, Stelma-
chowska et al. did not prove a statistically significant
relationship between the levels of growth hormone
(GH), insulin-like growth factor 1 (IGF-1), and disease
duration in relation to aberrations in carbohydrate me-
tabolism. Only the age of the patients proved to be stat-
ically significant (the older the patient, the more fre-
quent the occurrence of aberrations in carbohydrate me-
tabolism). Bierin et al. also assumed that the age of pa-
tients was a major risk factor in the development of
aberrations in carbohydrate metabolism [11].
In this study a significant increase in the percentage
of patients with type 2 diabetes in the age subgroup
under 60 years of age was observed when compared to
the ones with normoglycaemia (60% v. 20%). In patients
under 60 years of age the proportions in each of the
subgroups were reversed, i.e. the ratio of patients with
normoglycaemia to the ones with type 2 diabetes was
on average 64% to 21%.
There was a great number of studies in which it was
observed that patients with type 2 diabetes coinciding
with acromegaly were on average ten years older than
the ones with acromegaly coinciding with normogly-
caemia [2, 12].
In our study almost the same results were obtained.
In the examined group of 70 patients with recognized
acromegaly, the average age of patients with type 2 di-
abetes co-occurring was 56.1 years, whereas in those
Table III. Occurrence of aberrations in carbohydrate metabolism in patients with acromegaly according of age
Tabela III. Występowanie zaburzeń gospodarki węglowodanowej u pacjentów z akromegalią w zależności od wieku
Aged group (years) Number of patients Normoglycaemia IFG + IGT Type 2 diabetes mellitus
n = 70 n = 40 n = 11 n = 19
20–30 6 4 (66%) 1 (16.6%) 1 (16.6%)
31–50 25 16 (64%) 3 (12%) 6 (24%)
51–60 29 18 (62%) 5 (17%) 6 (20.6%)
> 60 10 2 (20%) 2 (20%) 6 (60%)
Table IV. Average fasting, postprandial and twenty-four-hour glycaemia in patients with acromegaly and type 2 diabetes
mellitus
Table IV. Średni poziom glikemii na czczo, poposiłkowej i dobowej u pacjentów z akromegalią i cukrzycą typu 2
Patients with type 2 Average fasting Average postprandial Average twenty-four-hour
diabetes mellitus  glucose  glycaemia glycaemia
All (n = 19) 128 mg/dL 163 mg/dL 158 mg/dL
Female (n = 10) 126 mg/dL 141 mg/dL 149 mg/dL
Male (n = 9) 130 mg/dL 189 mg/dL 169 mg/dL
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without aberrations in carbohydrate metabolism it was
47.1 years of age. This difference seemed to be smaller
in males than in females (F — 55 v. 50.8; M — 57.3 v. 36).
Conclusions
In patients with acromegaly the incidence rate of type
2 diabetes is 3–4 times higher than in the rest of the
population and increases with age, especially in people
aged 60 years and over.
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